Non-alcoholic fatty liver disease (NAFLD) is increasingly common due to the rising prevalence of obesity in both children and adults. It is associated with metabolic risk factors such as diabetes mellitus, dyslipidaemia and hypertension, and is associated with increased mortality both from cardiovascular-related and liver-related deaths. Identifi cation of those individuals with signifi cant infl ammation and fi brosis is a critical part of the patient pathway. Current treatments for NAFLD include weight loss from lifestyle modifi cation or bariatric surgery, management of underlying metabolic risk factors and for those with end stage liver disease, liver transplantation.
Introduction
Non-alcoholic fatty liver disease (NAFLD), defi ned as accumulation of fat in the liver in the absence of excessive alcohol consumption, is now the most common cause of liver disease in the western world, affecting up to 30% of the population. 1 The prevalence of NAFLD rises further in adults with obesity (57-98%) and diabetes (69%) refl ecting the strong association with metabolic syndromes. 1, 2 Less common causes include use of total parenteral nutrition, rapid weight loss as in the case of jejunoileal or gastric bypass, endocrine disorders (eg polycystic ovarian syndrome, hypothyroidism or hypopituitarism) and usage of drugs such as corticosteroids, oestrogens, anti-retrovirals and tetracycline. Notably there are marked differences in prevalence of NAFLD across ethnic groups, with Hispanic persons having the highest prevalence, followed by non-Hispanic whites, and then African Americans who have the lowest rate of NAFLD. 3 NAFLD captures a spectrum of disease ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and on to fi brosis/cirrhosis with the risk of hepatocellular carcinoma. 4 Data thus far suggest that NAFLD progresses to NASH in about 20% of cases, of which 20-25% may progress on to more advanced stages of hepatic fibrosis and cirrhosis, although predicting which individual patients will progress to develop advanced fi brosis is challenging. 4 Factors such as higher BMI/weight gain, older age, male gender and presence of metabolic risk factors are associated with higher/worsening levels of fi brosis in cohort studies and recent work has identifi ed genetic polymorphisms that are associated with a higher risk of developing liver fi brosis.
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Pathogenesis
Although there have been multiple hypotheses addressing the pathogenesis of NAFLD, describing up to three 'hits' for NASH to develop, there is consensus that a common fi rst hit is the hepatic accumulation of triglycerides and free fatty acids. This leads on to the generation of toxic reactive oxygen species, release of infl ammatory cytokines and mitochondrial dysfunction, which then lead to initiation and progression to steatohepatitis and fi brosis. 4 An allele in palatin-like
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KEYWORDS: Non-alcoholic fatty liver disease, cirrhosis, obesity, insulin resistance, treatment ■ phospholipase domain-containing 3 gene (PNPLA3) has been strongly associated with increased hepatic fat levels and hepatic infl ammation. 7 This allele was most common in Hispanics, the group most susceptible to NAFLD and it has been reported that the rs738409 CG allele is the most frequent gene variant and common in individuals with NASH. 8 
When to intervene?
The majority of patients with NAFLD have simple steatosis with no evidence of NASH or fi brosis, and current data would indicate that this cohort is not at an increased risk of liver disease. 5 Thus, the challenge is to identify which patients have evidence of NASH/fi brosis so that investigation and treatment can be appropriately targeted. While patients with NAFLD commonly have mildly abnormal liver function tests (LFTs), which is often the way by which they are identifi ed, the absolute elevations of transaminases/γ-glutamyl transferase (GGT) are not useful in identifying patients with more advanced disease. 9 Disease stratifi cation can be undertaken by using one of many available algorithms which commonly utilise an aspartate transaminase (AST)/alanine transaminase (ALT) ratio. 10 Notably the value of the AST/ALT ratio in identifying patients with liver fi brosis holds true even in the setting of normal transaminases. 11, 12 Such algorithms have an excellent negative predictive value albeit with a poorer positive predictive value, and are therefore often combined with an additional non-invasive assessment of liver fi brosis such as transient elastography. 13 In cases where there is either diagnostic uncertainty, or where confi rmation of advanced disease is useful, then liver biopsy should be requested. A potential algorithm for the investigation of such patients is illustrated in Fig 1. Current and future therapies for NASH are summarised in Table 1 .
What to intervene with?
There are no licensed therapies specifi cally for the management of NAFLD, and therefore current approaches are based on lifestyle management and management of associated comorbidities in anticipation of future pharmacological developments.
Lifestyle modifi cations
A reduction in weight of at least 3-5% has been demonstrated to result in improvements in biochemical indices in patients with NAFLD, while a reduction of at least 10% is needed to show histological improvements in necroinfl ammation. A range of different strategies have been utilised with the most effective combining calorifi c reduction, behavioural modifi cation and exercise, which highlights the importance of behavioural interventions. Such approaches will need to be supplemented by governmental initiatives as outlined by the Academy of Medical Royal Colleges.
14 As yet, lifestyle interventions have not demonstrably impacted on liver fi brosis although this is likely to require continuation of any measure for a more prolonged period of time than has been undertaken thus far. Notably, exercise without any associated weight loss has also been shown to result in improvements in liver biochemistry and steatosis in NAFLD, which is likely a consequence of improved insulin glucose control, insulin sensitivity and fatty acid oxidation. 15 Use of pharmacological agents to achieve weight loss in patients with NAFLD has not been particularly successful. Orlistat, a lipase inhibitor, had been demonstrated to improve liver biochemistry and hepatic steatosis in one study, 16 although a subsequent study revealed no effect on weight nor liver histology. Post-hoc analysis in this latter study revealed that weight loss of >9% was associated with histological improvement suggesting that there may be benefi t in a time-limited trial of orlistat in some patients. However, given potential issues with fat malabsorption and vitamin D defi ciency, caution should be exercised before commencing orlistat, which should be undertaken in conjunction with expert dietary input.
Pharmacological therapies
Metformin
The varied actions of metformin make it an ideal candidate for the treatment of NAFLD; it decreases hepatic gluconeogenesis, increases muscle glucose uptake and enhances fatty acid oxidation in the adipose tissue. However, meta-analysis of studies combining metformin and lifestyle intervention found it did not improve aminotransferases or liver histology, as compared with lifestyle intervention alone. 17 Notably, this fi nding was independent of metformin dose or the presence of diabetes. Thus, despite these studies being relatively small in size and likely underpowered, usage of metformin is reserved for those patients with concomitant type 2 diabetes mellitus rather than as a specifi c treatment for NAFLD.
Thiazolidinediones
Agents from the thiazolidinedione (TZD) family act principally by enhancing insulin sensitivity through an action on peroxisome proliferator activated receptor-γ and increasing circulating adiponectin levels. Smaller studies and a recent meta-analysis indicate that TZDs (mainly pioglitazone) are effective in improving both biochemistry and liver histology in patients with NAFLD. 17 However, in the largest study included in the meta-analysis, the PIVENS trial, pioglitazone did not meet the primary endpoint of histological improvement. 18 Moreover, there remain concerns about the long-term safety of TZDs with regard to weight gain, osteoporosis, and use in patients with cardiac failure and bladder cancer, which have tempered enthusiasm for their use. Nevertheless, pioglitazone remains a potential therapeutic agent to specifi cally treat NAFLD in patients, although its long-term usage in this setting remains to be established.
Incretin-based therapies
Incretins are produced by the intestinal tract in response to food ingestion, where they stimulate glucose-dependent insulin release, decrease glucagon release and prolong gastric emptying, resulting in weight loss, improved insulin sensitivity and glycaemic control. The most common therapeutic agents used are long-acting glucagon-like peptide-1 (GLP-1) analogues, such as exenatide and liraglutide, which have been licensed for the treatment of diabetes mellitus. Studies indicate this class of drugs is safe and potentially effective, with potential in the treatment of NAFLD, 19 although there are no controlled trials reported with histological outcome data yet.
Cytoprotective and antioxidant agents
Ursodeoxycholic acid Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid with cytoprotective and antioxidant properties. UDCA looked encouraging in phase 2 studies, however, when studied in a large randomised multicentre trial there was no histological benefi t over placebo. 20 
Vitamin E
The anti-oxidant, vitamin E (α-tocopherol), has been demonstrated to be effective in two large randomised controlled trials (TONIC and PIVENS) in non-diabetic paediatric and adult populations respectively. [21] [22] [23] While both studies showed a signifi cant reduction in histological hepatocellular infl ammation and ballooning with vitamin E, there remains uncertainty about their use in diabetic patients, as well as concerns about the safety of doses >400 IU/day which have been shown to increase all-cause mortality.
Lipid-lowering agents
A number of studies have demonstrated that statins can be used safely in the treatment of dyslipidaemia in patients with NASH. However, there are no studies assessing the effect of statins on liver histology, and therefore they cannot be recommended as a specifi c treatment for NASH. 24, 25 Bariatric surgery
There are no randomised controlled trials of bariatric surgery in patients with NASH, with published data coming from meta-analyses of cohort series. These series indicate histological improvement in steatosis, lobular infl ammation and ballooning, with confl icting outcomes for liver fi brosis. 26, 27 Further studies are required to establish the role and type of bariatric surgery in patients with NASH.
Liver transplantation
NASH accounts for an increasing proportion of patients undergoing liver transplantation, despite the associated comorbidities in this cohort. Patient survival is good and, while recurrent steatosis may be common, rates of graft loss due to recurrent disease are minimal. 28 
Conclusion
With rising obesity levels, the prevalence of NAFLD continues to rise, although the majority of such patients will not develop signifi cant liver disease. For those patients progressing to NASH and advanced fi brosis, intensifi cation of lifestyle management remains the mainstay, while new treatments are tested in clinical trials. ■
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